curl-6 on 12 November 2020
A vaccine from Canada-based Medicago starts combined Phase 2/3 trials: https://www.gsk.com/en-gb/media/press-releases/medicago-and-gsk-announce-start-of-phase-23-clinical-trials-of-adjuvanted-covid-19-vaccine-candidate/
| vivster said: There are a number of factors why we're seeing very few cases of reinfection. 1. The majority of covid cases have happened very recently 2. covid survivors are more likely to take measures to prevent another infection 3. a second infection may be less likely to have strong symptoms 4. some new infections may already be reinfections but are impossible to detect as such |
There would still be way more verified cases of reinfection than there have been if it didn't confer any real immunity.
